Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response in therapy of NSCLC patients (CROSBI ID 573135)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Pavićević, Radomir, Bubanović, Gordana ; Krajna, Ana ; Miličić, Jasna ; Bialk, Peter ; Pavićević, Lukrecija ; Stančić-Rokotov, Dinko Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response in therapy of NSCLC patients // The European respiratory journal. Supplement / Cosio, M, et al (ur.). 2001. str. 377s-377s

Podaci o odgovornosti

Pavićević, Radomir, Bubanović, Gordana ; Krajna, Ana ; Miličić, Jasna ; Bialk, Peter ; Pavićević, Lukrecija ; Stančić-Rokotov, Dinko

engleski

Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response in therapy of NSCLC patients

In this study we presented the dynamics of tumor marker CYFRA 21-1 level that is evaluyted as a response to therapy (surgery and chemotherapy) in 500 NSCLC patients. Serum level of CYFRA 21-1 was measured with electrochemiluminescence method using fully automated system Elecsys 2010 (Roche Diagnostics). The level of CYFRA 21-1 in NSCLC patients was determined before and after the therapy. In 95% surgically treated patients we observed a significant decrease of CYFRA 21-1 level after the therapy to the average level of healthy population (p<0, 001). In 5% patients the increase of CYFRA 21-1 level was observed after the surgery which indicated the tumor biological activity. This allowed the clinicians to apply an additional therapy. From 141 patients who underwent surgery followed by chemotherapy in 35% CYFRA 21-1 level indicated the inefficiency of therapy which was also proved clinically. This allowed the clinicians to replace the applied chemotherapy. Introducing the protocol including the evaluation of CYFRA 21-1 level before and after therapy we proved the contribution of tumor marker CYFRA 21-1 to the selection and control of therapy and the assessment of therapy efficiency.

CYFRA 21-1; NSCLC

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

377s-377s.

2001.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

The European respiratory journal. Supplement

Cosio, M, et al

Sheffield: European Respiratory Society

1-904097-02-2

0904-1850

Podaci o skupu

11th ERS annual congress

poster

22.09.2001-26.09.2001

Berlin, Njemačka

Povezanost rada

Kliničke medicinske znanosti, Biologija

Indeksiranost